Hillsdale Investment Management Inc. Purchases 39,800 Shares of Exelixis, Inc. $EXEL

Hillsdale Investment Management Inc. grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 93.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 82,300 shares of the biotechnology company’s stock after buying an additional 39,800 shares during the period. Hillsdale Investment Management Inc.’s holdings in Exelixis were worth $3,627,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EXEL. Truist Financial Corp lifted its position in shares of Exelixis by 1.1% during the second quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock worth $983,000 after purchasing an additional 250 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Exelixis by 0.3% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after purchasing an additional 274 shares during the last quarter. Frank Rimerman Advisors LLC lifted its holdings in Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 285 shares in the last quarter. Rathbones Group PLC boosted its position in Exelixis by 5.3% in the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 347 shares during the period. Finally, Plato Investment Management Ltd boosted its position in Exelixis by 6.5% in the 2nd quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock valued at $271,000 after buying an additional 377 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group initiated coverage on shares of Exelixis in a report on Wednesday, September 17th. They issued a “buy” rating and a $47.00 price target for the company. Truist Financial decreased their price objective on Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a research report on Tuesday, October 21st. Finally, Barclays upped their price objective on shares of Exelixis from $40.00 to $41.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $45.45.

Exelixis Price Performance

Exelixis stock opened at $42.51 on Friday. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62. The stock has a market capitalization of $11.40 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. The business has a 50 day simple moving average of $39.86 and a 200-day simple moving average of $40.63.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million during the quarter, compared to analyst estimates of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director directly owned 21,380 shares in the company, valued at approximately $896,463.40. The trade was a 53.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the completion of the transaction, the director owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 173,005 shares of company stock worth $7,443,678. Insiders own 2.82% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.